Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

J Neurooncol. 1992 Feb;12(2):187-91. doi: 10.1007/BF00172671.

Abstract

Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Brain Neoplasms / drug therapy*
  • Cisplatin / administration & dosage*
  • Drug Evaluation
  • Female
  • Glioma / drug therapy*
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Nitroso Compounds / therapeutic use*

Substances

  • Nitroso Compounds
  • N-(2-chloroethyl)-N-nitrosoacetamide
  • Cisplatin